The Pharmaceutical Company Outlook to 2011: Financial and Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech

Questions: Discounts, Updates etc.

Price: $7,600.00

Publication Date: 2006-12-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Based on an analysis of 46 companies and 1,000+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 4.9% CAGR 200511. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening.


Scope

  • Financial and Strategic Analysis of the Sales Outlook to 2011 for Big Pharma, Mid Pharma, Japan Pharma and Biotech
  • Quantitative analysis of the revenue balance of launches and expiries for each peer set member to 2011
  • Assessment of current and forecast 2011 therapeutic focus and product type focus for each peer set member
  • 2002-2006 operating cost and EBIT margin analysis for each peer set member


    • Report Highlights
    Faced with failing growth, Big Pharma is expected to pursue strategic options including operational cost efficiencies, M&A with other Big Pharma companies, biotech, Mid Pharma CNS players and/or generics manufacturers and acquisitional moves outside of 'pharma space' to increase presence in medical devices, diagnostics and consumer healthcare.

    Biotech will be the fastest growing peer set with a 10.1% sales CAGR 2005-11. Biotech is almost totally insulated from generic threat because (1) biotech portfolios are often too young to contain expired products and (2) even if products have expired, the predominantly biologic nature of biotech portfolios is a major barrier to generic entry.

    The fastest growing Japanese companies (such as Daiichi-Sankyo and Astellas) will receive the majority of their growth from expanding sales of already marketed products whereas the slowest growing companies (such as Takeda and Eisai) are burdened with heavy sales declines from patent expiries particularly in the gastrointestinal therapy area.


    Reasons to Purchase

  • Understand the strategic motives behind the recent wave of Big Pharma acquisitions of monoclonal antibody companies
  • Identify the rare examples of promising high growth CNS products located in the Mid Pharma peer set
  • Learn how biotech faces slowing growth momentum due to second generation biologics cannibalizing sales of first generation predecessor products

    • Table of Contents

    Other users found this report page using the following search terms: japan japanese pharmaceutical market generic entry oncology astellas outlook s ga pharma japan ma motives

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.